Eli Lilly and Company (LLY)vsYD Bio Ltd (YDES)
LLY
Eli Lilly and Company
$1,160.11
-2.33%
HEALTHCARE · Cap: $1.03T
YDES
YD Bio Ltd
$7.42
-2.50%
HEALTHCARE · Cap: $539.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 6428207% more annual revenue ($79.67B vs $1.24M). LLY leads profitability with a 33.5% profit margin vs 24.7%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
YDES
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 314.9% year-over-year
Conservative balance sheet, low leverage
Keeps 25 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -66.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : YDES
The strongest argument for YDES centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at -382.1%. Revenue growth of 314.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : YDES
The primary concerns for YDES are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
YDES is growing revenue faster at 314.9% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 32/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →YD Bio Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?